Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.
Exelixis Inc (EXEL) has a market cap of $11.91B with year-over-year revenue growth of +7.0%. Net margin stands at 33.7%. The stock trades at a P/E ratio of 15.2.
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, EXEL posted revenue growth of +7.0% and trades at a P/E of 15.2.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.